Asset Details
Do you wish to reserve the book?
Immunopathogenesis of lymphoma : Focus on CCR4
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immunopathogenesis of lymphoma : Focus on CCR4
Do you wish to request the book?
Immunopathogenesis of lymphoma : Focus on CCR4
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immunopathogenesis of lymphoma : Focus on CCR4
2011
Overview
Evading immune surveillance is one of the common hallmarks of cancer. Herein we describe two major evasion mechanisms in lymphoma, focusing on regulatory T (Treg) cells and C‐C chemokine receptor 4 (CCR4) expressed on these cells. First, the tumor cells themselves function as Treg cells, characterized by expression of CCR4, contributing to tumor survival by downregulating host immunity. Second, CCR4 ligands are produced by tumor cells, which attract other CCR4+ Treg cells to the vicinity of the tumor. CCR4+ adult T‐cell leukemia//lymphoma is an example of the former phenomenon, and Hodgkin lymphoma of the latter, for which an almost identical immunopathogenesis has been reported in many types of cancer. Awareness of the importance of CCR4 allows the rational design of more effective cancer treatments. Accordingly, we have developed a defucosylated anti‐CCR4 mAb, the first therapeutic agent targeting CCR4 to be used clinically for cancer. The therapeutic anti‐CCR4 mAb represents a promising treatment method for patients with CCR4+ neoplasms by directly killing the cancer cells, but could also be used as a novel treatment strategy for many types of CCR4− cancers to overcome the suppressive effect of CCR4+ Treg cells. (Cancer Sci 2011; 102: 44–50)
Publisher
Blackwell Publishing Ltd,Blackwell
Subject
/ Biological and medical sciences
/ Cell Transformation, Neoplastic
/ Hematologic and hematopoietic diseases
/ Hodgkin Disease - immunology
/ Human T-lymphotropic virus 1 - pathogenicity
/ Humans
/ Leukemia-Lymphoma, Adult T-Cell - immunology
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Lymphoma, Large B-Cell, Diffuse - immunology
/ Lymphoma, T-Cell, Peripheral - immunology
/ Mice
/ Protein-Tyrosine Kinases - analysis
/ Receptor Protein-Tyrosine Kinases
/ Receptors, CCR4 - antagonists & inhibitors
/ Receptors, CCR4 - physiology
/ T-Lymphocytes, Regulatory - immunology
/ Tumors
